Skip to main content
REGN logo

REGN

Compare

Regeneron Pharmaceuticals Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite ®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

Did you know?

Profit margin of 31.4% — that's well above average.

Current Price

$766.02

+2.60%

GoodMoat Value

$1382.84

80.5% undervalued
Profile
Valuation (TTM)
Market Cap$80.51B
P/E17.87
EV$71.51B
P/B2.58
Shares Out105.10M
P/Sales5.61
Revenue$14.34B
EV/EBITDA12.82

Regeneron Pharmaceuticals Inc (REGN) Financial Statements

REGN Financial Data

EBITDA$5.82B
Revenue (TTM)$14.34B
Gross Profit (TTM)$12.24B
Gross Margin
Operating Margin24.95%
ROE14.41%
ROA11.11%
Debt/Equity0.09
Current Ratio4.13
FCF$4.08B
FCF Yield5.07%
Piotroski F-Score
Rev/Share (TTM)$136.47
50-Day MA$763.70
200-Day MA$677.69
Shares Outstanding0.11B

REGN Computed Insights

FCF
FCF Growth Rate
EPS Growth (CAGR)
WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

REGN Financial Statements & Data

Regeneron Pharmaceuticals Inc (REGN) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Regeneron Pharmaceuticals Inc's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $14.34B. Gross profit (TTM) is $12.24B. EBITDA is $5.82B. Earnings per share (EPS) is $41.48. The P/E ratio is 17.87. Market capitalization is $80.51B.

Weighted average cost of capital (WACC) is 10.00%.

GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Regeneron Pharmaceuticals Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.